FAQs – on Ranitidine tablets and injections in India

Manufacturers of Ranitidine tablets and Injections should get their products tested for the presence of impurities i.e.  N-Nitrosodimethylamine (NDMA).

1003
FAQs
Picture: Pixabay
Deputy State Drugs Controller |
Food and Drugs Administration, Haryana, India. |
Email ID: fdazone@gmail.com
Lalit Kr. Goel

Last Updated on December 3, 2023 by The Health Master

Ranitidine tablets and Injections

Q. What is the status of sale of Ranitidine tablet/ injection in India

Ans:
Ranitidine is a schedule H drug available in the market in the form of tablet and injections.

Govt. of India has not banned it under section 26 A of the Drugs and Cosmetics Act.

As per DCGI office letter dated 13 September 2019 that Ranitidine formulation contains N-Nitrosodimethylamine (NDMA) which is an impurity cause cancer.

Manufacturers / formulators of Ranitidine tablets and Injections should get their products tested for the presence of impurities i.e.  N-Nitrosodimethylamine (NDMA).

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news